Inhibition of PAF protects mice from anaphylaxis while maintaining tumor protection provided by DTA-1 as part of a combination therapy. C57BL/6J mice were challenged intradermally with 1 × 105 B16 melanoma cells. Groups of mice were either left untreated (naive) or were treated with 200 µg TA99 on days 5 and 9 after tumor challenge, 1 mg DTA-1 on days 5, 9, and 16 after tumor challenge, or a combination of both TA99 and DTA-1 at the aforementioned doses and schedules. One group treated with TA99 plus DTA-1 received 125 µg CV6209 by intraperitoneal injection in PBS 30 minutes before the day 16 dose of DTA-1. (A) Rectal temperatures were monitored following the day 16 dose of DTA-1. (B) Tumor growth was measured every 2 to 3 days, represented by individual lines in the graphs. Mice were euthanized when tumor diameter reached 1 cm. Data are representative of 3 independent experiments (n = 15 mice per group). *P < .05, unpaired 2-tailed Student t test.
